Boehringer/Lilly To Price Tradjenta On Par With Rival DPP-4 Inhibitors
Executive Summary
Boehringer Ingelheim GMBH and Eli Lilly & Co. are likely to play up simplicity of dosing for the just-approved DPP-4 inhibitor Tradjenta (linagliptin) in a launch planned for the end of May, and expect to price the drug on par with others in the class.
You may also be interested in...
Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin
Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.
Manufacturing Woes Result In “Complete Response” For Lilly’s Empagliflozin
Some analysts expect it could take six months to resolve problems at partner Boehringer Ingelheim’s German manufacturing site, where the SGLT-2 inhibitor is made. Lilly says the European filing is not affected.
Lilly Disappoints Street, But Stays Its Course
Eli Lilly & Co. failed to meet the Street’s expectations on Jan. 5 when it held a guidance call with analysts, largely due to the rapid erosion of its newly genericized antipsychotic Zyprexa.